New platform aims to unlock secrets of advanced melanoma

NCT ID NCT06463509

Completed Knowledge-focused Sponsor: Reinhard Dummer Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study involved 116 people with advanced melanoma. Researchers aimed to create a platform that goes beyond standard genetic testing to deeply profile tumors using advanced molecular technologies. The goal was to discover new biomarkers and help doctors make better treatment recommendations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this platform could help doctors better match advanced melanoma patients with effective treatments by providing detailed molecular profiles.
What could go wrong: This was an early exploratory study focused on setting up the platform, not testing a treatment. The findings may not directly improve patient outcomes or be widely applicable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA

Contacts and locations

Show contact details

Locations

Department of Dermatology, University Hospital Zurich

Zurich, Canton of Zurich, 8091, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.